Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 87 Breast Neoplasms 49 Prostatic Neoplasms 42 Squamous Cell Carcinoma of Head and Neck 34 Lung Neoplasms 24 Neoplasms 19 Stomach Neoplasms 18 Head and Neck Neoplasms 17 Neoplasm Metastasis 16 Parkinson Disease 4, Autosomal Dominant Lewy Body 14 Urinary Bladder Neoplasms 13 Carcinoma, Transitional Cell 11 Triple Negative Breast Neoplasms 10 Ovarian Neoplasms 8 Endometrial Neoplasms 8 Carcinoma, Squamous Cell 8 Adenocarcinoma 8 HER2-positive Breast Cancer 7 Non-Muscle Invasive Bladder Neoplasms 6 Melanoma 6 Carcinoma 6 Small Cell Lung Carcinoma 5 Prostatic Neoplasms, Castration-Resistant 5 Nasopharyngeal Carcinoma 5 Esophageal Neoplasms 5 Uterine Cervical Neoplasms 4 Sarcoma 4 Oropharyngeal Neoplasms 4 Fallopian Tube Neoplasms 4 Esophageal Squamous Cell Carcinoma 4

Interventions

Gemcitabine 3 Cisplatin 3 Carboplatin 3 pembrolizumab 2 erdafitinib 2 vinflunine 1 tremelimumab 1 enfortumab vedotin 1 durvalumab 1 avelumab 1 atezolizumab 1 Tiragolumab 1 Nivolumab 1 Midazolam 1 Metformin 1 Ipilimumab 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Urothelial Cancer × Docetaxel × 1 year × Clear all

NCT03390504 2026-05-11

THOR

Janssen Research & Development, LLC

Phase 3 Active not recruiting

629 enrolled 32 charts

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡